Matches in Wikidata for { <http://www.wikidata.org/entity/Q64222983> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- Q64222983 description "clinical trial" @default.
- Q64222983 description "ensayu clínicu" @default.
- Q64222983 description "klinisch onderzoek" @default.
- Q64222983 description "клінічне випробування" @default.
- Q64222983 description "կլինիկական փորձարկում" @default.
- Q64222983 name "A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Can" @default.
- Q64222983 type Item @default.
- Q64222983 label "A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Can" @default.
- Q64222983 prefLabel "A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Can" @default.
- Q64222983 P1132 Q64222983-8C8254F0-A467-4C0B-A542-65127D472B47 @default.
- Q64222983 P1476 Q64222983-11340B6F-3C37-4223-A79C-447DC1DB6F4D @default.
- Q64222983 P17 Q64222983-03D32727-F772-422B-999E-2E043C74F60F @default.
- Q64222983 P17 Q64222983-04F1C6E1-85F7-4035-8FB5-8637AEE6F323 @default.
- Q64222983 P17 Q64222983-1337C492-13BE-4000-84C9-B1281D077C94 @default.
- Q64222983 P17 Q64222983-1D8C0797-C09B-409F-8EF7-77D71035D2EB @default.
- Q64222983 P17 Q64222983-210659D5-70F6-4FFF-9003-A7CF0302C6B3 @default.
- Q64222983 P17 Q64222983-4301C87E-AE39-4EF4-B78A-CA5BCEF9C421 @default.
- Q64222983 P17 Q64222983-43FDBAA9-47CC-4AAB-8EBA-62A59B17BB83 @default.
- Q64222983 P17 Q64222983-4C5E48B3-E89B-4EFB-8C3D-7E58B327477A @default.
- Q64222983 P17 Q64222983-5A323FFC-B433-4823-A904-5E11CBB1A521 @default.
- Q64222983 P17 Q64222983-7107A984-C088-476C-8A4E-66D018D7AF7E @default.
- Q64222983 P17 Q64222983-730DA759-5775-4410-A6AF-0411389A4082 @default.
- Q64222983 P17 Q64222983-943547D7-F2F3-41BE-A537-6B3F46FDCA92 @default.
- Q64222983 P17 Q64222983-95407C5B-390E-468F-B3B2-5A551F90D0EB @default.
- Q64222983 P17 Q64222983-9FF09251-2D69-41D4-9159-F9E09EB5EE5A @default.
- Q64222983 P17 Q64222983-A158C4DD-95B9-4CF4-8B47-4E3CCE7028BB @default.
- Q64222983 P17 Q64222983-C28F13F4-FA80-4502-BC4C-AD1A490D954F @default.
- Q64222983 P17 Q64222983-C69647D7-C898-486E-BAD5-FACBA272A3B9 @default.
- Q64222983 P17 Q64222983-DA2F737F-A31A-4366-999E-EB3EB0F59CB8 @default.
- Q64222983 P17 Q64222983-DAB9720C-0495-4E54-B022-57F1FFCFD087 @default.
- Q64222983 P17 Q64222983-DB2B7FC0-4F48-4E1F-8DDA-4CC8724F8593 @default.
- Q64222983 P17 Q64222983-E529B604-1D5A-4C3D-A5D1-5DF516ED73D5 @default.
- Q64222983 P17 Q64222983-E5715F44-3F85-480F-8931-788E518CFD5D @default.
- Q64222983 P17 Q64222983-E7042C95-37C4-4804-839D-DF455C66AA9A @default.
- Q64222983 P17 Q64222983-E8723694-30BB-4074-8D50-8BF0A0F2219A @default.
- Q64222983 P17 Q64222983-EDA1F58A-7A89-4C78-BF9C-A6AA319E9656 @default.
- Q64222983 P17 Q64222983-F088AD33-2FBC-4DA9-A5B1-E1F889047BF0 @default.
- Q64222983 P1813 Q64222983-8B2DDBD7-E8F3-4B07-94DE-83240997E486 @default.
- Q64222983 P3098 Q64222983-D2F87D54-1A32-4D2F-B0F3-728F63BAC1BF @default.
- Q64222983 P31 Q64222983-2AED2D23-66BF-4C8E-9434-6F89FA29048F @default.
- Q64222983 P580 Q64222983-0240AFC3-C12A-4D27-9E03-7E4FC3F5DABF @default.
- Q64222983 P582 Q64222983-D9139534-7A3D-48D9-8A78-BCC43F83661F @default.
- Q64222983 P8363 Q64222983-0219F8C1-909F-470A-8CDC-0B0771E24152 @default.
- Q64222983 P921 Q64222983-B1F8AC21-AB42-4462-B549-24F1C2819DBC @default.
- Q64222983 P1132 "+1533" @default.
- Q64222983 P1476 "A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk for Poor Clinical Outcomes After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-Resistant Prostate Cancer and Men With Metastatic Prostate Cancer at Initial Diagnosis" @default.
- Q64222983 P17 Q142 @default.
- Q64222983 P17 Q145 @default.
- Q64222983 P17 Q155 @default.
- Q64222983 P17 Q16 @default.
- Q64222983 P17 Q183 @default.
- Q64222983 P17 Q252 @default.
- Q64222983 P17 Q262 @default.
- Q64222983 P17 Q29 @default.
- Q64222983 P17 Q334 @default.
- Q64222983 P17 Q38 @default.
- Q64222983 P17 Q40 @default.
- Q64222983 P17 Q408 @default.
- Q64222983 P17 Q414 @default.
- Q64222983 P17 Q419 @default.
- Q64222983 P17 Q55 @default.
- Q64222983 P17 Q664 @default.
- Q64222983 P17 Q739 @default.
- Q64222983 P17 Q79 @default.
- Q64222983 P17 Q801 @default.
- Q64222983 P17 Q822 @default.
- Q64222983 P17 Q842 @default.
- Q64222983 P17 Q851 @default.
- Q64222983 P17 Q865 @default.
- Q64222983 P17 Q869 @default.
- Q64222983 P17 Q928 @default.
- Q64222983 P17 Q96 @default.
- Q64222983 P1813 "ASPIRE-PCa" @default.
- Q64222983 P3098 "NCT02066961" @default.
- Q64222983 P31 Q30612 @default.
- Q64222983 P580 "2013-12-31T00:00:00Z" @default.
- Q64222983 P582 "2019-11-01T00:00:00Z" @default.
- Q64222983 P8363 Q818574 @default.
- Q64222983 P921 Q55779807 @default.